Nosocomial transmission of coronavirus disease 2019: a retrospective study of 66 hospital-acquired cases in a London teaching hospital

HM Rickman, T Rampling, K Shaw… - Clinical infectious …, 2021 - academic.oup.com
Coronavirus disease 2019 (COVID-19) can cause deadly healthcare-associated outbreaks.
In a major London teaching hospital, 66 of 435 (15%) COVID-19 inpatient cases between 2 …

A monovalent chimpanzee adenovirus Ebola vaccine—preliminary report

T Rampling, K Ewer, G Bowyer, D Wright… - New England Journal …, 2015 - ora.ox.ac.uk
Background The West African outbreak of Ebola virus disease has caused more than 8500
deaths. A vaccine could contribute to outbreak control in the region. We assessed a …

[HTML][HTML] Clinical features and management of human monkeypox: a retrospective observational study in the UK

…, CF Houlihan, JC Osborne, T Rampling… - The Lancet Infectious …, 2022 - thelancet.com
Background Cases of human monkeypox are rarely seen outside of west and central Africa.
There are few data regarding viral kinetics or the duration of viral shedding and no licensed …

[HTML][HTML] Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV …

…, M Pacurar, A Palfreeman, D Pan, T Rampling… - The Lancet, 2021 - thelancet.com
Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a …

…, N Turner, NYY Ting, S Whittley, T Rampling… - The Lancet, 2021 - thelancet.com
Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation. However, we have previously reported that heterologous …

[HTML][HTML] Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B. 1.1. 7 lineage in London, UK: a whole-genome sequencing and hospital-based …

D Frampton, T Rampling, A Cross, H Bailey… - The Lancet infectious …, 2021 - thelancet.com
Background Emergence of variants with specific mutations in key epitopes in the spike
protein of SARS-CoV-2 raises concerns pertinent to mass vaccination campaigns and use of …

[HTML][HTML] Family cluster of three cases of monkeypox imported from Nigeria to the United Kingdom, May 2021

…, C Johnson, D Porter, T Rampling… - …, 2021 - eurosurveillance.org
Most reported cases of human monkeypox occur in Central and West Africa, where the
causing virus is endemic. We describe the identification and public health response to an …

[HTML][HTML] COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study

…, H Peckham, M Marks, T Rampling… - The Lancet …, 2020 - thelancet.com
Background A subset of patients with severe COVID-19 develop a hyperinflammatory
syndrome, which might contribute to morbidity and mortality. This study explores a specific …

[HTML][HTML] Genomic investigations of unexplained acute hepatitis in children

…, S Castellano, P Chikowore, M Odam, T Rampling… - Nature, 2023 - nature.com
Since its first identification in Scotland, over 1,000 cases of unexplained paediatric hepatitis
in children have been reported worldwide, including 278 cases in the UK 1 . Here we report …

[HTML][HTML] Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 …

…, A Palfreeman, D Pan, T Rampling… - The Lancet Infectious …, 2022 - thelancet.com
Background Some high-income countries have deployed fourth doses of COVID-19 vaccines,
but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We …